These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
365 related articles for article (PubMed ID: 36039385)
1. Distinct Molecular Mechanisms Characterizing Pathogenesis of SARS-CoV-2. Lee SJ; Kim YJ; Ahn DG J Microbiol Biotechnol; 2022 Sep; 32(9):1073-1085. PubMed ID: 36039385 [TBL] [Abstract][Full Text] [Related]
2. Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19). Ahn DG; Shin HJ; Kim MH; Lee S; Kim HS; Myoung J; Kim BT; Kim SJ J Microbiol Biotechnol; 2020 Mar; 30(3):313-324. PubMed ID: 32238757 [TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies. Gong W; Parkkila S; Wu X; Aspatwar A Int Rev Immunol; 2023; 42(6):393-414. PubMed ID: 35635216 [TBL] [Abstract][Full Text] [Related]
4. Current Therapeutics for COVID-19, What We Know about the Molecular Mechanism and Efficacy of Treatments for This Novel Virus. Narayanan D; Parimon T Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887042 [TBL] [Abstract][Full Text] [Related]
5. Progress and Challenges in the Development of COVID-19 Vaccines and Current Understanding of SARS-CoV-2- Specific Immune Responses. Kim KD; Hwang I; Ku KB; Lee S; Kim SJ; Kim C J Microbiol Biotechnol; 2020 Aug; 30(8):1109-1115. PubMed ID: 32627758 [TBL] [Abstract][Full Text] [Related]
6. Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update. Anand U; Jakhmola S; Indari O; Jha HC; Chen ZS; Tripathi V; Pérez de la Lastra JM Front Immunol; 2021; 12():658519. PubMed ID: 34276652 [TBL] [Abstract][Full Text] [Related]
7. An evidence-based systematic review on emerging therapeutic and preventive strategies to treat novel coronavirus (SARS-CoV-2) during an outbreak scenario. Gudadappanavar AM; Benni J J Basic Clin Physiol Pharmacol; 2020 Sep; 31(6):. PubMed ID: 32924964 [TBL] [Abstract][Full Text] [Related]
8. Advances in Pathogenesis, Progression, Potential Targets and Targeted Therapeutic Strategies in SARS-CoV-2-Induced COVID-19. Zhou H; Ni WJ; Huang W; Wang Z; Cai M; Sun YC Front Immunol; 2022; 13():834942. PubMed ID: 35450063 [TBL] [Abstract][Full Text] [Related]
9. COVID-19: Vaccines and therapeutics. Ponnampalli S; Venkata Suryanarayana Birudukota N; Kamal A Bioorg Med Chem Lett; 2022 Nov; 75():128987. PubMed ID: 36113669 [TBL] [Abstract][Full Text] [Related]
10. Recent Advances in N-Heterocycles for COVID-19 Treatment - A Mini Review. Dinodia M Med Chem; 2023; 19(8):717-729. PubMed ID: 36852805 [TBL] [Abstract][Full Text] [Related]
11. [Diagnosis, treatment, control and prevention of SARS-CoV-2 and coronavirus disease 2019: back to the future]. Ye ZW; Jin DY Sheng Wu Gong Cheng Xue Bao; 2020 Apr; 36(4):571-592. PubMed ID: 32347053 [TBL] [Abstract][Full Text] [Related]
12. Host Protective Immunity against Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) and the COVID-19 Vaccine-Induced Immunity against SARS-CoV-2 and Its Variants. Noor R Viruses; 2022 Nov; 14(11):. PubMed ID: 36423150 [TBL] [Abstract][Full Text] [Related]
13. Transmissibility and pathogenicity of SARS-CoV-2 variants in animal models. Kim YI; Casel MAB; Choi YK J Microbiol; 2022 Mar; 60(3):255-267. PubMed ID: 35235177 [TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 ORF8: A Rapidly Evolving Immune and Viral Modulator in COVID-19. Arduini A; Laprise F; Liang C Viruses; 2023 Mar; 15(4):. PubMed ID: 37112851 [TBL] [Abstract][Full Text] [Related]
15. Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments. Abdurrahman L; Fang X; Zhang Y Curr Mol Med; 2022; 22(7):621-639. PubMed ID: 34645374 [TBL] [Abstract][Full Text] [Related]
16. The novel zoonotic COVID-19 pandemic: An expected global health concern. Contini C; Di Nuzzo M; Barp N; Bonazza A; De Giorgio R; Tognon M; Rubino S J Infect Dev Ctries; 2020 Mar; 14(3):254-264. PubMed ID: 32235085 [TBL] [Abstract][Full Text] [Related]
17. Perspectives on development of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Zhang C; Zhou C; Shi L; Liu G Hum Vaccin Immunother; 2020 Oct; 16(10):2366-2369. PubMed ID: 32961082 [TBL] [Abstract][Full Text] [Related]
18. Leveraging on the genomics and immunopathology of SARS-CoV-2 for vaccines development: prospects and challenges. Abdullahi IN; Emeribe AU; Adekola HA; Abubakar SD; Dangana A; Shuwa HA; Nwoba ST; Mustapha JO; Haruna MT; Olowookere KA; Animasaun OS; Ugwu CE; Onoja SO; Gadama AS; Mohammed M; Daneji IM; Amadu DO; Ghamba PE; Onukegbe NB; Shehu MS; Isomah C; Babayo A; Ahmad AE Hum Vaccin Immunother; 2021 Mar; 17(3):620-637. PubMed ID: 32936732 [TBL] [Abstract][Full Text] [Related]
19. [Update on COVID-19 in 2021]. Zhou M; Qu JM Zhonghua Jie He He Hu Xi Za Zhi; 2022 Jan; 45(1):67-71. PubMed ID: 35000308 [TBL] [Abstract][Full Text] [Related]
20. Approaches and advances in the development of potential therapeutic targets and antiviral agents for the management of SARS-CoV-2 infection. Krishna G; Pillai VS; Veettil MV Eur J Pharmacol; 2020 Oct; 885():173450. PubMed ID: 32739174 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]